0R2B Stock Overview
Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Danaher Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$241.62 |
52 Week High | US$283.88 |
52 Week Low | US$191.32 |
Beta | 0.86 |
11 Month Change | -11.87% |
3 Month Change | -12.01% |
1 Year Change | 25.11% |
33 Year Change | -20.49% |
5 Year Change | 79.26% |
Change since IPO | 218.15% |
Recent News & Updates
Recent updates
Shareholder Returns
0R2B | GB Life Sciences | GB Market | |
---|---|---|---|
7D | -3.5% | 0.2% | -1.1% |
1Y | 25.1% | -19.9% | 10.2% |
Return vs Industry: 0R2B exceeded the UK Life Sciences industry which returned -19.9% over the past year.
Return vs Market: 0R2B exceeded the UK Market which returned 10.2% over the past year.
Price Volatility
0R2B volatility | |
---|---|
0R2B Average Weekly Movement | 2.9% |
Life Sciences Industry Average Movement | 4.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 9.4% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R2B has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0R2B's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1969 | 62,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
Danaher Corporation Fundamentals Summary
0R2B fundamental statistics | |
---|---|
Market cap | US$175.02b |
Earnings (TTM) | US$3.93b |
Revenue (TTM) | US$23.74b |
44.5x
P/E Ratio7.4x
P/S RatioIs 0R2B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0R2B income statement (TTM) | |
---|---|
Revenue | US$23.74b |
Cost of Revenue | US$9.53b |
Gross Profit | US$14.22b |
Other Expenses | US$10.28b |
Earnings | US$3.93b |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.45 |
Gross Margin | 59.87% |
Net Profit Margin | 16.57% |
Debt/Equity Ratio | 34.2% |
How did 0R2B perform over the long term?
See historical performance and comparison